Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity

Amplification and overexpression of the neu (c-erbB2) proto-oncogene has been implicated in the pathogenesis of 20 to 30% of human breast cancers. Although the activation of Neu receptor tyrosine kinase appears to be a pivotal step during mammary tumorigenesis, the mechanism by which Neu signals cell proliferation is unclear. Molecules bearing a domain shared by the c-Src proto-oncogene (Src homology 2) are thought to be involved in signal transduction from activated receptor tyrosine kinases such as Neu. To test whether c-Src was implicated in Neu-mediated signal transduction, we measured the activity of the c-Src tyrosine kinase in tissue extracts from either mammary tumors or adjacent mammary epithelium derived from transgenic mice expressing a mouse mammary tumor virus promoter/enhancer/unactivated neu fusion gene. The Neu-induced mammary tumors possessed six- to eightfold-higher c-Src kinase activity than the adjacent epithelium. The increase in c-Src tyrosine kinase activity was not due to an increase in the levels of c-Src but rather was a result of the elevation of its specific activity. Moreover, activation of c-Src was correlated with its ability to complex tyrosine-phosphorylated Neu both in vitro and in vivo. Together, these observations suggest that activation of the c-Src tyrosine kinase during mammary tumorigenesis may occur through a direct interaction with activated Neu.

[1]  R. Pepperkok,et al.  The Src family tyrosine kinases are required for platelet-derived growth factor-mediated signal transduction in NIH 3T3 cells. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[2]  T. Pawson,et al.  SH2 domains recognize specific phosphopeptide sequences , 1993, Cell.

[3]  M. Roussel,et al.  Activation of Src family kinases by colony stimulating factor‐1, and their association with its receptor. , 1993, The EMBO journal.

[4]  R. Cardiff,et al.  Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[5]  G. Staal,et al.  Characterization of protein tyrosine kinases from human breast cancer: involvement of the c-src oncogene product. , 1992, Cancer research.

[6]  K. Helin,et al.  erbB-2 autophosphorylation is required for mitogenic action and high-affinity substrate coupling. , 1992, Oncogene.

[7]  J. H. Wang,et al.  A synthetic peptide derived from p34cdc2 is a specific and efficient substrate of src-family tyrosine kinases. , 1992, The Journal of biological chemistry.

[8]  M. Moran,et al.  Multiple SH2-mediated interactions in v-src-transformed cells , 1992, Molecular and cellular biology.

[9]  R. Cardiff,et al.  Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease , 1992, Molecular and cellular biology.

[10]  S. Shurtleff,et al.  Myc rescue of a mutant CSF-1 receptor impaired in mitogenic signalling , 1991, Nature.

[11]  Anton Berns,et al.  Identification of cooperating oncogenes in Eμ-myc transgenic mice by provirus tagging , 1991, Cell.

[12]  C. Molloy,et al.  The erbB-2 mitogenic signaling pathway: tyrosine phosphorylation of phospholipase C-gamma and GTPase-activating protein does not correlate with erbB-2 mitogenic potency , 1991, Molecular and cellular biology.

[13]  A. Harris,et al.  c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. , 1991, British Journal of Cancer.

[14]  Allan Bradley,et al.  Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice , 1991, Cell.

[15]  R. Fourney,et al.  Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. , 1991, Cancer research.

[16]  S. Courtneidge,et al.  Association between the PDGF receptor and members of the src family of tyrosine kinases , 1990, Cell.

[17]  J. Pierce,et al.  Transformation of NIH 3T3 cells by overexpression of the normal coding sequence of the rat neu gene , 1990, Molecular and cellular biology.

[18]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[19]  A. Berns,et al.  Predisposition to lymphomagenesis in pim-1 transgenic mice: Cooperation with c-myc and N-myc in murine leukemia virus-induced tumors , 1989, Cell.

[20]  Cori Bargmann,et al.  Oncogenic activation of the neu‐encoded receptor protein by point mutation and deletion. , 1988, The EMBO journal.

[21]  P. Leder,et al.  Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene , 1988, Cell.

[22]  A. Ullrich,et al.  Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[23]  C R King,et al.  erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. , 1987, Science.

[24]  Cori Bargmann,et al.  The neu oncogene encodes an epidermal growth factor receptor-related protein , 1986, Nature.

[25]  P. Cohen,et al.  Analysis of pp60c-src protein kinase activity in human tumor cell lines and tissues. , 1986, The Journal of biological chemistry.

[26]  Cori Bargmann,et al.  Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185 , 1986, Cell.

[27]  N. Nomura,et al.  Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor , 1986, Nature.

[28]  P. Seeburg,et al.  Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. , 1985, Science.

[29]  K. Semba,et al.  A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[30]  R. Weinberg,et al.  The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. , 1985, Science.

[31]  C R King,et al.  Amplification of a novel v-erbB-related gene in a human mammary carcinoma. , 1985, Science.

[32]  P. Leder,et al.  Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes , 1984, Cell.

[33]  H. Rübsamen,et al.  Expression of pp60c-src protein kinase in adult and fetal human tissue: high activities in some sarcomas and mammary carcinomas. , 1983, Cancer research.

[34]  R. Cardiff,et al.  Transgenic mouse models of mammary tumorigenesis. , 1993, Cancer surveys.

[35]  S. Courtneidge,et al.  Association of Fyn with the activated platelet-derived growth factor receptor: requirements for binding and phosphorylation. , 1992, Oncogene.

[36]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[37]  Mahlon D. Johnson,et al.  Elevated content of the tyrosine kinase substrate phospholipase C-yl in primary human breast carcinomas , 2022 .